Inogatran

Inogatran

Chemical structure of Inogatran

Inogatran is a synthetic anticoagulant that functions as a direct thrombin inhibitor. It is primarily used in the prevention and treatment of thromboembolic disorders.

Mechanism of Action

Inogatran works by directly inhibiting the activity of thrombin, an enzyme that plays a central role in the coagulation cascade. By binding to the active site of thrombin, Inogatran prevents the conversion of fibrinogen to fibrin, thereby inhibiting the formation of blood clots.

Pharmacokinetics

Inogatran is administered intravenously and has a rapid onset of action. It is metabolized in the liver and excreted primarily through the kidneys. The half-life of Inogatran allows for convenient dosing schedules in clinical settings.

Clinical Uses

Inogatran is used in various clinical scenarios, including:

• Prevention of deep vein thrombosis (DVT) in patients undergoing major orthopedic surgery.
• Treatment of pulmonary embolism (PE).
• Management of patients with atrial fibrillation to reduce the risk of stroke.

Side Effects

Common side effects of Inogatran include:

• Bleeding complications, which are the most significant risk associated with its use.
• Nausea and vomiting.
• Hypotension in some patients.

Contraindications

Inogatran should not be used in patients with:

• Active bleeding disorders.
• Severe renal impairment.
• Known hypersensitivity to the drug.

Comparison with Other Anticoagulants

Inogatran is part of a class of drugs known as direct thrombin inhibitors, which also includes agents like dabigatran and argatroban. Compared to warfarin, Inogatran has a more predictable pharmacokinetic profile and does not require regular INR monitoring.

Related Pages

• Thrombin
• Anticoagulant
• Coagulation
• Deep vein thrombosis
• Pulmonary embolism